WASHINGTON — In a significant regulatory development concerning one of the world’s most widely utilized and heavily debated herbicides, the United States Department of Health and Human Services (HHS) and the Environmental Protection Agency (EPA) have officially announced a joint interagency Memorandum of Understanding (MOU). This collaborative agreement aims to fortify scientific coordination, pool toxicological expertise, and rigorously re-evaluate the human health impacts and registration status of glyphosate.
The partnership marks a pivotal pivot in how federal authorities evaluate agrochemicals. By bridging the vast public health apparatus of the HHS—specifically leveraging the specialized capabilities of the National Institute of Environmental Health Sciences (NIEHS)—with the regulatory authority of the EPA, the Biden-Harris administration is positioning the upcoming 2027 health risk assessment as one of the most comprehensive and scrutinized reviews in the history of American pesticide regulation.
Main Facts
The core of the newly established interagency framework centers on enhanced data sharing, transparent scientific peer review, and targeted toxicological investigation regarding glyphosate and its associated commercial formulations.
- The Interagency Partnership: The MOU establishes a formal mechanism for the HHS and the EPA to exchange complex scientific data, identify critical research gaps, and jointly analyze the multifaceted impacts of glyphosate on human health.
- Leadership and Coordination: Under the terms of the agreement, the HHS will designate a senior official from the NIEHS to spearhead its institutional participation. Concurrently, the EPA will appoint senior leadership from its Office of Pesticide Programs to coordinate regulatory insights.
- Preservation of Authority: While the agreement heavily integrates external scientific expertise, the EPA retains sole and exclusive statutory authority for pesticide registration and regulatory decisions under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). The MOU does not confer any new regulatory authorities to either participating agency.
- Timeline for Completion: The EPA is actively updating its human health risk assessment and comprehensive evaluation of glyphosate as a potential carcinogen, with a finalized report slated for release in early 2027.
- Public Transparency: To ensure public trust and accountability, all relevant materials generated by the interagency working groups will be systematically published in the public regulatory docket (EPA-HQ-OPP-2009-0361) on a rolling basis. Additionally, the EPA has released an open, comprehensive literature-search protocol for public comment to guide its ongoing risk updates.
Chronology of Regulatory Scrutiny and Scientific Evolution
The path toward the current HHS-EPA Memorandum of Understanding is rooted in decades of scientific debate, legal challenges, and evolving regulatory frameworks governing agricultural chemicals in the United States and internationally.
Early Registrations and FIFRA Mandates (1970s–2000s)
Glyphosate was first commercialized in the 1970s as a broad-spectrum, non-selective systemic herbicide designed to eradicate annual and perennial weeds. Under FIFRA, the EPA is legally mandated to periodically re-evaluate registered pesticides to ensure they do not pose unreasonable adverse effects on human health or the environment, taking into account contemporary scientific standards. Throughout the late 20th century, initial reviews consistently permitted its widespread agricultural, commercial, and residential use, establishing it as a cornerstone of modern farming practices, particularly following the introduction of genetically modified, glyphosate-tolerant crops in the mid-1990s.
The IARC Classification and Global Divergence (2015)
A major watershed moment occurred in March 2015, when the International Agency for Research on Cancer (IARC)—a specialized intergovernmental agency of the World Health Organization (WHO)—classified glyphosate as "probably carcinogenic to humans" (Group 2A). This determination sparked global controversy, placing the IARC’s conclusions at loggerheads with various national regulatory bodies, including the EPA and the European Food Safety Authority (EFSA), which historically maintained that glyphosate was unlikely to pose a carcinogenic risk to humans when used according to label instructions.
Litigative Pressures and Court-Ordered Remands (2016–2022)
The divergence between international cancer classifications and domestic regulatory approvals triggered an avalanche of high-profile product liability lawsuits across U.S. state and federal courts, filed by agricultural workers and consumers alleging that exposure to glyphosate-based products (such as Roundup) caused non-Hodgkin lymphoma. Parallel to civil litigation, environmental and public health coalitions repeatedly challenged the EPA’s interim registration review decisions in federal courts. In subsequent rulings, federal judges directed the EPA to re-examine specific elements of its human health and ecological risk assessments, specifically citing the need to address persistent scientific uncertainties regarding chronic exposure and vulnerable populations.
The Current Convergence (2024–Present)
Recognizing the imperative for an unassailable, highly transparent scientific foundation, the EPA and HHS elected to pool their institutional resources. The formalization of the interagency MOU in late 2024 / early 2025 represents a structural evolution in federal oversight—acknowledging that resolving complex toxicological questions requires breaking down historical agency silos and integrating the specialized biomedical research capabilities of the National Institutes of Health (NIH) network with the operational mandate of environmental regulators.
Supporting Data and Focus Areas of Collaboration
The scientific collaboration outlined in the MOU is not a broad, unfocused review; rather, it targets specific, high-priority areas where supplementary research and cross-agency coordination can substantially bolster the evidentiary baseline available to the EPA.
1. Toxicology of Formulations and Co-Formulants
While regulatory assessments historically focused heavily on the active ingredient (glyphosate in its acid or salt forms), growing scientific inquiry has shifted toward commercial pesticide formulations. These formulations frequently incorporate surfactants—chemical agents designed to help the active ingredient penetrate plant leaves more effectively. The interagency collaboration will systematically review the comparative toxicology of whole formulations versus isolated active ingredients, investigating whether certain surfactants independently exacerbate toxicological endpoints.
2. Human Exposure Pathways and Biomonitoring
Understanding how humans absorb, metabolize, and excrete glyphosate is critical for accurate risk modeling. The EPA and HHS will evaluate comprehensive data concerning:
- Occupational Exposure: Assessing long-term exposure levels among agricultural workers, commercial applicators, and landscape professionals through biomonitoring studies.
- Dietary Exposure: Evaluating residues present in food supplies, with specific emphasis on pre-harvest applications where crops are desiccated with glyphosate shortly before harvesting.
- General Population Exposure: Reviewing urinary biomonitoring data from broader public health cohorts to gauge baseline environmental absorption rates.
3. Endpoints of Toxicological Concern
The collaborative research teams will dedicate extensive analytical resources to scrutinizing available empirical evidence across several sensitive biological endpoints, including:
- Carcinogenicity: Re-analyzing epidemiological cohorts and laboratory animal bioassays to determine cancer risk profiles.
- Genotoxicity: Assessing the potential for glyphosate and its co-formulants to induce DNA damage or chromosomal aberrations.
- Reproductive and Developmental Toxicity: Investigating potential endocrine-disrupting properties and effects on fetal development, fertility, and generational health outcomes.
Official Responses and Perspectives
The announcement of the interagency accord has drawn diverse reactions from government officials, scientific stakeholders, agricultural sectors, and public health advocacy groups.
Environmental Protection Agency Perspective
EPA Administrator Lee Zeldin emphasized that the agency’s primary obligation under FIFRA is to ground its regulatory decisions in the absolute highest quality and most current scientific evidence available.
"Our commitment is to ensure that every pesticide registration review is transparent, rigorous, and uncompromised by outside pressures," Zeldin noted. "By partnering directly with the Department of Health and Human Services and drawing upon the unmatched biomedical expertise of the NIEHS, we are ensuring that our upcoming human health risk assessments are fortified by exhaustive, peer-reviewed science that the American public can trust."
Health and Human Services Perspective
Leadership within the HHS echoed the sentiment, framing the partnership as a vital interdisciplinary bridge that connects foundational public health research with environmental regulation. By assigning senior scientists from the NIEHS to coordinate the initiative, the department underscores its dedication to uncovering the long-term, chronic health implications of environmental chemical exposures.
Agricultural and Industrial Stakeholders
Representatives from the agricultural sector and agrochemical manufacturers have expressed cautious interest, emphasizing the necessity for predictability, consistency, and scientific objectivity in regulatory decision-making. For modern commercial agriculture, glyphosate remains an indispensable tool for no-till farming, soil conservation, and weed management. Industry groups maintain that decades of global scientific review have overwhelmingly demonstrated the safety of the herbicide when used in accordance with approved safety guidelines, while noting their willingness to engage constructively with the updated EPA review process.
Environmental and Public Health Advocates
Conversely, environmental health organizations and consumer safety advocates have cautiously welcomed the increased involvement of public health agencies like the HHS. For years, advocacy groups have argued that traditional pesticide reviews conducted solely within the EPA framework historically understated risks associated with chronic, low-level exposures and commercial formulation adjuvants. They view the direct inclusion of biomedical researchers as a crucial step toward a more holistic evaluation of potential public health hazards.
Implications of the Interagency Agreement
The establishment of the HHS-EPA Memorandum of Understanding carries profound implications for the future of chemical regulation, agricultural practices, and public policy in the United States and beyond.
1. Setting a New Precedent for Interagency Synergy
Historically, federal agencies have frequently operated within rigid regulatory silos, occasionally resulting in conflicting scientific interpretations or duplicated efforts between environmental regulators and public health institutions. The MOU creates a working blueprint for how complex, contentious regulatory questions can be addressed through institutional cooperation, pooling specialized toxicological capabilities to eliminate blind spots in safety evaluations.
2. Impact on the 2027 Risk Assessment and Beyond
The immediate practical outcome of this collaboration will be the delivery of the EPA’s updated human health risk assessment in early 2027. Because this assessment will incorporate an open literature-search protocol, peer-reviewed biomonitoring data, and rigorous evaluations of formulations from health experts, its conclusions will carry immense legal, scientific, and commercial weight. Should the assessment identify previously underappreciated risks, it could trigger downstream regulatory restrictions, label modifications, or localized use prohibitions. Conversely, a reaffirmed safety profile backed by both environmental and public health agencies could stabilize regulatory uncertainty for agricultural producers.
3. Public Transparency and Restoring Institutional Trust
By mandating the continuous publication of working group materials within public regulatory dockets, the EPA and HHS are taking proactive measures to address historical criticisms regarding transparency in pesticide reviews. In an era where public trust in regulatory institutions is continually tested, open-access protocols and collaborative cross-agency science serve to depoliticize risk assessment and ground policy in verifiable, peer-reviewed data.
As the scientific working groups mobilize under the leadership of the NIEHS and the EPA’s Office of Pesticide Programs, the global scientific community will be watching closely. The outcome of this unprecedented collaboration will not only determine the regulatory future of glyphosate in the United States but will also set a definitive benchmark for how modern industrial democracies evaluate the complex intersections of agriculture, environmental protection, and public health.
Leave a Reply